INO logo

INOVIO PHARMACEUTICALS INC

INONASDAQ
πŸ† #4001 by market capEarnings Nov 9US Equity
$0.77β–Ό $0.16 (βˆ’16.89%)
πŸŒ™ After hours$0.76β–Ό 1.04%Regular close Β· extended-hours price shown
πŸ””
Track INO
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 16.9%
7dβ–Ό 8.0%
14dβ–Ό 26.1%
30dβ–Ό 31.1%
ytdβ–Ό 55.8%
1yβ–Ό 68.2%
🏦Market Cap
$80M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
58.9%
Healthy
πŸ’΅FCF Margin
5172.3%
Strong
βš–οΈP/S Ratio
318.4x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.61 – $0.97
52-Week Range
$0.56 – $2.72
Volume (shares)
9,496,219
Avg Volume (shares)
β€”
Shares Outstanding
103.4M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
$65,343
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
318.4x
EPS (TTM)
$-1.17
Dividend Yield
β€”
Dilution (1yr)
+112.6%
INO logo

INOVIO PHARMACEUTICALS INC

INO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$65Kβ–Ό βˆ’70.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$87Mβ–Ό βˆ’22.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$89Mβ–Ό βˆ’15.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
69.0Mβ–² +112.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$35Mβ–Ό βˆ’$19M YoY
StockOtter Β· stockotter.space

About INOVIO PHARMACEUTICALS INC

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy3
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

PRNewsWireΒ·9d ago

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people fromΒ HPV-r

Defense WorldΒ·28d ago

Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)

Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Inovio Pharmaceuticals (NASDAQ: INO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based

Zacks Investment ResearchΒ·Sep 14

Bet on 4 Top-Ranked Stocks With Rising P/E

Tap four stocks with increasing P/E ratios to try out an out-of-the-box investment approach.

Seeking AlphaΒ·Sep 11

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

MarketBeatΒ·Sep 11

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration re

MarketBeatΒ·Sep 10

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

Inovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor